Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898500 | 0.85 | PTPN7 (0.64) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29535608 | 0.85 | PTPN7 (0.64) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5065598 | 0.85 | NR1H4 (0.64) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8755920 | 0.82 | PLK1 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19TRPV1 | |
| SCHEMBL5681720 | 0.82 | ERCC1 (0.69) | TRPV1 | |
| SCHEMBL7715851 | 0.81 | SMN1; SMN2 (0.67) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5065591 | 0.81 | NR1H4 (0.60) | ALDH1A1TRPV1 | |
| SCHEMBL6566912 | 0.80 | HTR1A (0.69) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2858997 | 0.80 | CYP1A2 (0.61) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2858994 | 0.80 | CYP1A2 (0.61) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084176-B2 | N-arylphenylacetamide derivatives and medicinal compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20040248983-A1 | N-arylphenylacetamide derivatives and medicinal compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1403235-A1 | N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248983-A1 | N-arylphenylacetamide derivatives and medicinal compositions containing the same | HRH2, CCR8, CYP2C8 | ALDH1A1 684/4885CYP1A2 118/4885CYP3A4 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.